Novo Nordisk (NVO-0.32%) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working ...

President Trump threatened to levy a new 50% tariff on E.U.-imported goods last week. Novo Nordisk manufactures much of its GLP-1 drugs in Denmark. The president delayed implementation of the ...

Shares of Ozempic and Wegovy manufacturer Novo Nordisk (NYSE: NVO) reacted positively to the news and are up 4.9% as of 10:20 a.m. ET. Where to invest $1,000 right now?

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy and Ozempic, according to Danish media Finans.

President Trump threatened to levy a new 50% tariff on E.U.-imported goods last week. Novo Nordisk manufactures much of its GLP-1 drugs in Denmark. The president delayed implementation of the ...

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks. See why NVO stock is a Strong Buy.

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually ...

As for improving access to obesity treatments, Novo has, in recent months, brought down the out-of-pocket price for Wegovy. In March, it began offering a one-month supply to self-paying customers ...

A legal tangle hovers over Novo Nordisk’s diabetes and weightloss drug semaglutide, just weeks ahead of the possible launch of its injectible version Wegovy in India. Semaglutide is the active ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight ...

Novo Nordisk is locked in a patent infringement battle with Dr Reddy’s Laboratories and OneSource Specialty Pharma For a better experience, Read this story in our App Companies ...

Novo Nordisk’s hunt for boss with Danish values — and US commercial nous. Jørgensen’s ousting unusual for group where CEOs have had smooth transitions after long tenures.